60
Management
(cont'd)
Figure 11. Secondary ASCVD Prevention for Adults at
Very High Risk
* CVOTS pending; the majority of patients with ASCVD are at very high risk.
ASCVD indicates atherosclerotic cardiovascular disease; HDL-C, high-density lipoprotein-cholesterol;
LDL-C, low-density lipoprotein-cholesterol; mAb, monoclonal antibody; and PCSK9, proprotein
convertase subtilisin/kexin type 9.
Adapted with permission from Grundy at al. Copyright © 2018 American Heart Association, Inc. and
American College of Cardiology Foundation.
Clinical ASCVD at very
high risk (includes ASCVD
with CKD)
Optional apoB goal
<55 mg/dL
1
Start high-intensity or
maximally tolerated statin
Goal: ≥50% LDL-C reduction,
LDL-C <55 mg/dL, and
non–HDL-C <85 mg/dL
AND
